Please use this identifier to cite or link to this item: http://hdl.handle.net/10397/80732
Title: A randomized assessor-blinded wait-list-controlled trial to assess the effectiveness of acupuncture in the management of chemotherapy-induced peripheral neuropathy
Authors: Molassiotis, A 
Suen, LKP 
Cheng, HL 
Mok, TSK
Lee, SCY 
Wang, CH
Lee, P 
Leung, H
Chan, V
Lau, TKH
Yeo, W
Keywords: Acupuncture
Chemotherapy-induced peripheral neuropathy
Cancer
Neurotoxicity
Quality of life
Pain
Issue Date: 2019
Publisher: SAGE Publications
Source: Integrative cancer therapies, 2019, v. 18, p. 1-12 How to cite?
Journal: Integrative cancer therapies 
Abstract: Purpose: Chemotherapy-induced peripheral neuropathy is a complex side effect with few available treatment options. The aim of the study was to test the effectiveness of an 8-week course of acupuncture in the management of chemotherapy induced peripheral neuropathy in cancer patients who were receiving or had received neurotoxic chemotherapy.
Methods: Randomized assessor-blinded controlled trial with 2 arms; one arm received acupuncture twice weekly for 8 weeks, while the other arm was a wait-list control group receiving only standard care. Primary outcome was pain intensity and interference over the past week using the Brief Pain Inventory at the end of the intervention. Secondary outcomes included clinical assessment (CTCAE [Common Toxicity Criteria for Adverse Events] grading and Total Neuropathy Score–Clinical Version) and nerve conduction studies; and patient-reported outcome measures (Functional Assessment of Cancer Therapy–Gynecologic Oncology Group–Neurotoxicity Quality of Life scale and Symptom Distress Scale) assessed at baseline, end of treatment (8 weeks), week 14, and week 20 from the beginning of treatment.
Results: Eighty-seven patients were randomized to the experimental arm (n = 44) and to the standard care wait-list control arm (n = 43). Significant changes at 8 weeks were detected in relation to primary outcome (pain), the clinical neurological assessment, quality of life domains, and symptom distress (all P < .05). Improvements in pain interference, neurotoxicity-related symptoms, and functional aspects of quality of life were sustained in the 14-week assessment (P < .05), as were physical and functional well-being at the 20-week assessment (P < .05).
Conclusions: Acupuncture is an effective intervention for treating chemotherapy-induced peripheral neuropathy and improving patients’ quality of life and experience with neurotoxicity-related symptoms with longer term effects evident.
URI: http://hdl.handle.net/10397/80732
ISSN: 1534-7354
EISSN: 1552-695X
DOI: 10.1177/1534735419836501
Rights: © The Author(s) 2019 Article reuse guidelines: sagepub.com/journals-permissions
Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage)
The following publication Molassiotis, A., Suen, L. K. P., Cheng, H. L., Mok, T. S. K., Lee, S. C. Y., Wang, C. H., … Yeo, W. (2019). A randomized assessor-blinded wait-list-controlled trial to assess the effectiveness of acupuncture in the management of chemotherapy-induced peripheral neuropathy. Integrative Cancer Therapies, 18, 1-12 is published by Sage and is available at https://dx.doi.org/10.1177/1534735419836501
Appears in Collections:Journal/Magazine Article

Files in This Item:
File Description SizeFormat 
Molassiotis_Assessor-Blinded_Trial_Assess.pdf296.95 kBAdobe PDFView/Open
Access
View full-text via PolyU eLinks SFX Query
Show full item record
PIRA download icon_1.1View/Download Contents

Page view(s)

25
Citations as of Jul 16, 2019

Download(s)

16
Citations as of Jul 16, 2019

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.